The drug industry and health providers are divided over a freshly revised review process for resolving price fights after years of back-and-forth between presidential administrations and federal courts.
The Health and Human Services Department on Thursday announced a final rule (RIN 0906-AB28) that updates the administrative dispute resolution process for drugmakers and health providers participating in the federal 340B drug discount program.
Under the program, drugmakers are required to discount their products to covered medical providers such as hospitals, community health centers, and others supporting low-income populations.
The HHS positioned its effort as a way to make the 340B dispute ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.